← Back to Search

Intracardiac Echocardiography for Hypertrophic Cardiomyopathy

N/A

Waitlist Available

Led By Daniel Swistel, MD

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at the conclusion of all data collection; approximately 6 to 12 months

Awards & highlights

Study Summary

This trial is investigating whether or not a new intraoperative echocardiography technique called OPIE is as effective as traditional methods in measuring the thickness of the left ventricular septum in patients with hypertrophic cardiomyopathy.

Who is the study for?

This trial is for adults over 18 with hypertrophic cardiomyopathy scheduled for septal myectomy and have a thin interventricular septum (less than 2.0 cm wide) as shown by echocardiography. It's open to all genders and races.Check my eligibility

What is being tested?

The study tests on-pump intracardiac echocardiography (OPIE) against traditional transthoracic and transesophageal methods in measuring ventricular septal thickness during surgery for those with a thin septum.See study design

What are the potential side effects?

There are no direct side effects from the OPIE procedure itself, as it involves additional imaging during an already-planned surgery, adding less than five minutes to the operation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at the conclusion of all data collection; approximately 6 to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at the conclusion of all data collection; approximately 6 to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at the conclusion of all data collection; approximately 6 to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

correlations

Trial Design

1Treatment groups

Experimental Treatment

Group I: OPIE in thin inverventricular septumExperimental Treatment1 Intervention

The Principal Investigator use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,367 Previous Clinical Trials

839,701 Total Patients Enrolled

Daniel Swistel, MDPrincipal InvestigatorNYU Langone Health

Media Library

OPIE in thin inverventricular septum Clinical Trial Eligibility Overview. Trial Name: NCT04050579 — N/A

Hypertrophic Cardiomyopathy Research Study Groups: OPIE in thin inverventricular septum

Hypertrophic Cardiomyopathy Clinical Trial 2023: OPIE in thin inverventricular septum Highlights & Side Effects. Trial Name: NCT04050579 — N/A

OPIE in thin inverventricular septum 2023 Treatment Timeline for Medical Study. Trial Name: NCT04050579 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are enrolment applications being accepted for this investigation?

"The records on clinicaltrials.gov confirm that this trial is no longer recruiting participants, as the last update to it was dated August 8th 2022. Although, there are 168 other trials currently seeking volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

OPIE in the Thin Interventricular Septum

2020. "OPIE in the Thin Interventricular Septum". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04050579.

All > Hypertrophic Cardiomyopathy